NDAINJECTIONINJECTABLE1 Generic Approved
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDENE (nicardipine hydrochloride) is a dihydropyridine calcium channel blocker administered via injection for acute hypertension management. It works by inhibiting calcium influx into vascular smooth muscle cells, causing vasodilation and blood pressure reduction. The IV formulation is primarily used in hospital and acute care settings where rapid blood pressure control is required.
LOE Approaching1.5 years to LOE
Declining commercial opportunity with 1.5 years to patent expiry; brand team focus shifting toward lifecycle extension or managed decline strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on CARDENE at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.